While it is difficult to compare expression levels of various targets because of differing tumor samples, IHC protocols, and reagents, cell surface STEAP2 expression seems to be equivalent to or higher than the expression reported for other clinically tested prostate targets, including PSCA, PSMA, and STEAP1 (31–32). This evidence concerns the gene STEAP2 and neoplasm.